{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:54Z","timestamp":1792834734319,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study evaluates the diagnostic value of SATB2 and CDX2, used individually and in combination, in the immunohistochemical differential diagnosis of colorectal adenocarcinoma. A retrospective case-control diagnostic accuracy study was conducted, including 122 patients with histologically confirmed colorectal adenocarcinoma or non-colorectal adenocarcinoma. Immunohistochemical staining for SATB2 and CDX2 was performed on all cases, followed by semiquantitative interpretation. Using histopathological diagnosis as the gold standard, the diagnostic efficacy of each test index (SATB2 positive, CDX2 positive, either positive, and both positive) was calculated. SATB2 and CDX2 were highly expressed in colorectal adenocarcinoma (positive rates of 88.2% and 86.3%, respectively), which was significantly higher than in the control group (7.0% and 19.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). SATB2 used alone demonstrated the optimal diagnostic discrimination among single markers (AUC\u2005=\u20050.916, specificity 93.0%). Among the combined strategies, the \u201ceither positive\u201d rule achieved the highest sensitivity (94.1%), whereas the \u201cboth positive\u201d rule showed the highest specificity (98.6%) and overall discriminative ability (AUC\u2005=\u20050.938). PPV and NPV values were interpreted only within this case-control study population and should not be considered direct estimates of performance in populations with different disease prevalence. CDX2 showed the lowest specificity (60.0%) in differentiating gastric adenocarcinoma, whereas the \u201cboth positive\u201d strategy maintained high diagnostic reliability across all differential scenarios. The sensitivity of both markers was significantly reduced in poorly differentiated colorectal adenocarcinoma. SATB2 is an excellent single diagnostic marker. The combined application of SATB2 and CDX2 offers complementary advantages: \u201ceither positive\u201d is suitable for exclusion diagnosis, while \u201cboth positive\u201d is suitable for confirmation diagnosis. This combination is an effective tool for the differential diagnosis of colorectal adenocarcinoma, although caution is needed when diagnosing poorly differentiated carcinomas.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050180","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:13Z","timestamp":1787968873000},"page":"e50180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The value of combined SATB2 and CDX2 detection in the differential diagnosis of colorectal adenocarcinoma"],"prefix":"10.1097","volume":"105","author":[{"given":"Liping","family":"Wang","sequence":"first","affiliation":[{"name":"Shanghai Jince Medical Laboratory Co., Ltd, Shanghai City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Chifeng Municipal Hospital, Chifeng Clinical Medical School of Inner Mongolia Medical University, Chifeng City, Inner Mongolia Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8611-6131","authenticated-orcid":false,"given":"Liping","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang City, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality.","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer.","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3350\/cmh.2018.0067","article-title":"Pathologic differential diagnosis of metastatic carcinoma in the liver.","volume":"25","author":"Park","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/apm.12854","article-title":"SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.","volume":"126","author":"Dabir","year":"2018","journal-title":"APMIS"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2018.01.001","article-title":"SATB2 is a promising biomarker for identifying a colorectal origin for liver metastatic adenocarcinomas.","volume":"28","author":"Zhang","year":"2018","journal-title":"EBioMedicine"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ajcp\/aqx160","article-title":"Dual stain with SATB2 and CK20\/Villin is useful to distinguish colorectal carcinomas from other tumors.","volume":"149","author":"Li","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/diagnostics12030757","article-title":"Diagnostic and prognostic roles of CDX2 immunohistochemical expression in colorectal cancers.","volume":"12","author":"Choi","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3332\/ecancer.2022.1491","article-title":"Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study.","volume":"16","author":"Elnady","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.5858\/arpa.2018-0337-OA","article-title":"SATB2 versus CDX2: a battle royale for diagnostic supremacy in mucinous tumors.","volume":"143","author":"Brettfeld","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/modpathol.3800698","article-title":"Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.","volume":"19","author":"Vang","year":"2006","journal-title":"Mod Pathol"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAI.0000000000001216","article-title":"Use of SATB2 and CDX2 immunohistochemistry to characterize and diagnose colorectal cancer.","volume":"32","author":"Kato","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for pathologists: protocols, pitfalls, and tips.","volume":"50","author":"Kim","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.3390\/cancers13246177","article-title":"Loss of SATB2 occurs more frequently than CDX2 loss in colorectal carcinoma and identifies particularly aggressive cancers in high-risk subgroups.","volume":"13","author":"Schmitt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"105627","DOI":"10.1016\/j.humpath.2024.105627","article-title":"The utility of the lineage specific immunohistochemical stains SATB2, CDX2, and villin, and the mucin glycoproteins MUC2, MUC5AC, and MUC6 to distinguish pulmonary invasive mucinous adenocarcinoma from metastatic colorectal carcinoma.","volume":"151","author":"Rerkpichaisuth","year":"2024","journal-title":"Hum Pathol"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000478-200303000-00003","article-title":"CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.","volume":"27","author":"Werling","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41379-019-0265-1","article-title":"SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.","volume":"32","author":"Ma","year":"2019","journal-title":"Mod Pathol"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00262-025-03964-x","article-title":"CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer.","volume":"74","author":"Sirni\u00f6","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"152289","DOI":"10.1016\/j.anndiagpath.2024.152289","article-title":"Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.","volume":"71","author":"Lee","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00795-023-00366-9","article-title":"Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.","volume":"57","author":"Li","year":"2024","journal-title":"Med Mol Morphol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:01:30Z","timestamp":1792832490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":19,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050180","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-03-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}